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Abstract
Background
Systemic inflammation is associated with reduced quality of life and increased symptoms in
patients with advanced cancer. The aims of this study were to examine the relationships
between inflammatory biomarkers and the Patient Reported Outcome Measures (PROMs)
of pain, appetite and fatigue; and to explore whether levels of baseline biomarkers were
associated with changes in these PROMs following treatment with corticosteroids.
Material and methods
An exploratory analysis was done on a trial examining the analgesic properties of corticoste-
roids in patients with advanced cancer. Inclusion criteria were: >18 years, taking opioids for
moderate or severe cancer pain; pain4 (numerical rating scale 0–10). Serum was
extracted and levels of inflammatory biomarkers were assessed. PROMs of pain, appetite
and fatigue were assessed using the European Organisation for Research and Treatment
of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30). The relationships between
PROMs and inflammatory biomarkers were examined using Spearman Rho-Rank and mul-
tiple regression analysis.
Results
Data were available on 49 patients. Levels of sTNF-r1, IL-6, IL-18, MIF, MCP-1, TGF-β1, IL-
1ra, and C-reactive protein (CRP) and Erythrocyte sedimentation rate (ESR) were elevated;
IL-1β, IL-2, IL-4, IL-8, IL-10, IL-12(p70), interferon-γ, MIP-1α, and TNF-αwere below the
level of detection. The following correlations were observed: appetite and IL-6 and CRP;
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fatigue and IL-1ra (rs: 0.38–0.41, p< .01). There was no association between pretreatment
biomarkers and effect from corticosteroid treatment.
Conclusion
In patients with advanced cancer and pain, some pro-inflammatory cytokines were related
to appetite and fatigue. Inflammatory biomarkers were not associated with pain or with the
efficacy of corticosteroid therapy. Further research examining the attenuation of the sys-
temic inflammatory response and possible effects on symptoms would be of interest.
Introduction
Systemic inflammation has been described as the seventh “hallmark of cancer”[1]; necessary
for tumorigenesis and maintenance and progression of the cancer state. Symptoms such as
pain, cachexia, fatigue, cognitive impairment, anxiety and depression are common in patients
either in isolation or in combination, termed symptom clusters. The biological basis for these
symptom clusters has been postulated as being driven by the tumour-host interaction via the
systemic inflammatory response [2] akin to cytokine-induced sickness behavior (a set of physi-
ological and behavioral responses observed in sick individuals after the administration of
infectious or inflammatory agents or certain pro-inflammatory cytokines) [3].
Cytokines are key mediators and provide homeostasis and immune control as part of the
innate immune system through an intricate interplay with mutually dependent positive and
negative feedback mechanisms [4]. In healthy individuals, equilibrium exists between pro- and
anti-inflammatory cytokines. In advanced cancer, however, complex tumour-host interactions
disturb this equilibrium. Data from patients with advanced cancer show a cytokine pattern
indicating a state of simultaneous immunostimulation and immunosuppression. Pro-inflam-
matory cytokines predominate, finally resulting in increased concentrations of Macrophage
Migration Inhibitory Factor (MIF), Tumour Necrosis Factor α (TNF-α), interleukin (IL) -6,
IL-8, IL-10, IL-18, and Transforming Growth Factor β (TGF-β) in patients with advanced can-
cer [4].
Furthermore, study data have shown associations between serum concentrations of inflam-
matory biomarkers and symptoms in cancer patients. To illustrate, elevated level of C-reactive
protein (CRP) was associated with pain, anorexia, dyspnoea, and fatigue in patients with can-
cer [5, 6]. In another study, increased serum concentrations of soluble receptor 1 for tumor
necrosis factor (sTNF-r1) and IL-6 were related to an increase in the mean score for all 15
recorded symptoms, and in the five most severe symptoms, respectively, in patients with lung
cancer undergoing concurrent chemoradiotherapy [7]. Schubert and coworkers found cancer
related fatigue to be associated with elevated levels of biomarkers IL-6, IL-1 receptor antagonist
(IL-1ra) and neopterin [8]. Two other studies found that increased levels of IL-6 were associ-
ated with major depression in patients with lung cancer [9] and pancreatic cancer [10]; the lat-
ter study also found an association between the cytokines IL-1β, IL-4, and IL-12(p70) and pain
intensity, and between TGF-β and fatigue. Similarly, trials have indicated associations between
inflammatory gene variants and several symptoms. For instance, in a study of lung cancer
patients, gene variants for IL-8 and IL-10 were associated with pain, depressed mood and
fatigue [11].
So far, the associations between symptoms and specific biomarkers have not been consis-
tent, which may in part be due to use of cross-sectional study designs, inconsistency in
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measurements [12] and heterogeneous cancer patient populations. Despite these inconsisten-
cies, the relationship between symptoms and pro-inflammatory cytokines remains of interest
particularly in the light of recent work demonstrating the clear relationship between Patient
Reported Outcome Measures (PROMs) of quality of life and the systemic inflammatory
response [13]. Moreover, the relationship between individual pro-inflammatory cytokines and
PROMs of pain, appetite and fatigue is of interest, especially in the setting of anti-inflamma-
tory treatment with corticosteroids, which may have implications for the management of these
symptoms.
In clinical practice, anti-inflammatory drugs are often used for symptom control [14]. In
particular corticosteroids have been shown to improve appetite and fatigue in patients with
advanced cancer [15–17], and data from clinical trials support the use of corticosteroids for
1–2 weeks for these indications [15, 18]. With regard to the treatment of pain, a randomized
controlled trial found no analgesic effect of corticosteroids in cancer patients taking opioids
[17], whereas two studies have showed an analgesic effect [19], or temporarily increased pain
control [16]. A meta-analysis in a recently published Cochrane review concluded that cortico-
steroids could provide a mean reduction of pain intensity of 0.84 on a numeric rating scale
(NRS 0–10) (confidence interval, (CI) -1.38 to -0.3) after one week of treatment [20]. The
mechanisms of action are not well defined, but are thought to be mediated by their anti-
inflammatory effects.
The current study was a secondary exploratory analysis of a biobank established as part of a
randomized, controlled trial assessing the analgesic effects of methylprednisolone 32 mg daily
in patients with cancer pain on opioids [17].
Therefore, the primary aim of this study was to examine the relationship between inflam-
matory biomarkers (cytokines and markers of the inflammatory response) and PROMs of
pain, appetite and fatigue in patients with advanced cancer receiving opioids. A secondary aim
was to explore whether levels of baseline inflammatory biomarkers were associated with
changes in pain, appetite and fatigue following treatment with corticosteroids.
Materials and methods
Overall design
An exploratory analysis was undertaken on data from a randomized, double-blind, placebo
controlled trial examining the analgesic efficacy of corticosteroids in patients with advanced
cancer taking opioids [17]. Forty-nine patients were randomized to methylprednisolone 16
mg twice daily or placebo; 25 were evaluated in the corticosteroid arm, 22 were evaluated in
the placebo arm. Thirteen patients randomized to placebo received corticosteroids on an open
basis after the intervention period. PROMs from these patients were included in the analyses
at follow up after corticosteroid treatment. Ethical approval was given for the primary study by
the Regional Committee for Medical Research Ethics Central Norway (4.2007.846) and the
Norwegian Directorate of Health; Clinical trial information NCT00676936, EudraCT No
2007-005617-19. Procedures were conducted in accordance with the Declaration of Helsinki,
as revised in 1983. All patients provided written informed consent to their data being analysed
in line with the present study.
Eligible patients met the following criteria: >18 years of age, taking opioids for moderate or
severe cancer pain; cancer diagnosis; pain4 (on a 0–10 Numerical Rating Scale (NRS)) at
inclusion; expected survival > 4 weeks. Exclusion criteria included diabetes mellitus, peptic
ulcer disease, and concurrent use of non-steroidal anti-inflammatory drugs (NSAIDs) [17].
Inflammatory biomarkers were assessed at baseline, i.e. before corticosteroid treatment.
PROMs, were assessed at baseline and at follow up after 7 days of corticosteroid treatment
Cytokines and symptoms in patients with advanced cancer
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using the European Organisation for Research and Treatment of Cancer—Quality of Life
Questionnaire—C30 (EORTC QLQ-C30) [21]. The EORTC QLQ-C30 scores were calculated
according to the EORTC scoring manual [22], scores range from 0 to 100; a higher score corre-
sponds to a better health-related quality of life in the function scales (“better”), whereas a
higher score represents a higher levels of symptoms (“worse”) in the symptom scales. The
EORTC QLQ-C30 has been extensively validated in the cancer patient population and was
completed between 08:00 and 17:00 hours in all study patients.
The inflammatory markers and cytokines selected for the present study included high sensi-
tivity CRP, erythrocyte sedimentation rate (ESR), IL-1β, IL-1ra, IL-2, IL-4, IL-6, IL-8, IL-10,
IL-12(p70), IL-18, interferon-γ, TGF-β1, MIF, TNF-α, Macrophage Inflammatory Protein-1α
(MIP-1α), Monocyte Chemoattractant Protein-1 (MCP-1) and soluble Tumor Necrosis Factor
receptor-1 (sTNF-r1). sTNF-r1 was chosen because it reflects TNF-α-activity, since TNF-α is
among the most unstable cytokines [8, 23]. The cytokines were chosen on the basis of previous
research on cancer related inflammation and symptoms [7, 24, 25]. The sera underwent one
freeze-thaw cycle.
High sensitivity CRP analysis was performed at Fu¨rst laboratories, Oslo. The cytokine anal-
yses were performed at the Norwegian University of Life Sciences, Ås, using multiplex technol-
ogy (Multiplex System, Bio-Rad Laboratories Inc., Austin, Texas) in which serum cytokine
concentrations are measured in high-sensitivity assays. All samples were assayed in duplicate
and the assays performed according to manufacturer’s instructions by laboratory personnel
blinded to the rest of the data. Bio Rad Human Inflammation panels 6 plex kit containing IL-8,
IL-12(p70), IL-2, IL-10, interferon-γ, and sTNF-r1; Bio Rad human group 1 and 2 9 plex kit
containing IL-1β, IL-1ra, IL-4, IL-6, MCP-1, MIP-1α, TNF-α, IL-18, and MIF; and Bio Rad
singleplex kit TGF-β1 were used. In one patient one of the parallels in the 6 plex kit showed
very high values as compared to the other parallel (coefficient of variation: %CV 137–140
between the duplicates) and the other biomarkers from the same patient. This parallel was
therefore excluded from the analysis. Except from this, no significant variation was noted
between duplicates for any sample. The intra-assay CV was <10%. Cytokine / chemokine con-
centrations were interpolated from an appropriate standard curve. If the biomarker concentra-
tion was below the lowest point on the standard curve, we used the lowest value.
Statistical analyses
As this was an exploratory analysis no formal sample size calculation was performed. Where
appropriate, all data are reported as means with 95% confidence intervals (CIs), ranges, medi-
ans with interquartile ranges (IQRs), or frequencies. As the cytokines were not normally dis-
tributed, Spearman Rho-Rank was applied for the correlation analyses. Based on previous
research [26], sex, BMI, and age were explored as possible confounding factors in a multiple
regression model. Sex or BMI were associated (p< .05) with PROMs of fatigue, appetite, and
dyspnoea, and physical and role function scales, but did not change the results (data not
shown). Associations between pre-treatment inflammatory biomarker levels and changes in
pain, appetite, and fatigue following corticosteroid use were explored using multiple regression
analyses. Sex and BMI were included as covariates. In order to give some protection for multi-
ple testing, a significance level was set to p = .01. SPSS v21.0 (Chicago, IL) was used for all sta-
tistical analyses.
Results
Patient demographics, pain characteristics and analgesic use are shown in Table 1 (n = 49).
The mean age was 63.9 years (CI: 61.2–66.8), mean Karnofsky Performance Status score (KPS)
Cytokines and symptoms in patients with advanced cancer
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Table 1. Demographics and medical characteristics of the study participants.
Number of patients (n = 49) Mean Median CI
Sex Female 24
Male 25
Age Years 63.9 64.8 61.2–66.8
Weight kg 68.3 67.0 63.8–72.9
BMIa kg/m2 23.0 22.3 21.6–24.5
Ethnicity Caucasian 49
KPSb 66 70 62–70
Survival (days) 185 86 39–197 (IQR)c
Cancer diagnosis Gastrointestinal 14
Lung 11
Gynaecological 10
Prostate 6
Breast 2
Other 8
Metastases Liver 17
Bone 15
Lung 7
CNS 2
Other 33
No metastases 2
Oral opioid dose mg/24h mg (OME)d 230 135 165–296
Baseline opioid
Morphine 15 185 80 58–312
Oxycodone 19 148 110 98–198
Fentanyl 13 368 420 215–522
Other 2 459 459 -4198–5115
Corticosteroid medication n = 38
Methylprednisolone 34
Dexamethasone 2
Prednisolone 2
Dexamethasone equivalent mg 5.5 Range: 1.5–8
Concomitant disease 29
Cardiovascular 18
Lung 7
GI/Hepatic 5
Other 18
Other drugs
Peptic ulcer / Ulcer prophylaxis 19
Sleep medication 15
Anticoagulants 14
Acetylsalicylic acid 8
Cardiovascular 6
Statins 4
Hormones 3
Antidepressants 8
Antibiotics 1
Antifungal agents 3
(Continued )
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was 66 (CI: 62–70), median survival was 86 days (IQR: 39–197), mean body mass index (BMI)
was 23.0 (CI: 21.6–24.5), and mean opioid consumption 259 mg / day (oral morphine equiva-
lents) (CI: 178–339). Six patients received chemotherapy (Table 1). Data were available on 49
patients at baseline and on 38 patients at follow up having received methylprednisolone
(n = 34), dexamethasone (n = 2) or prednisolone (n = 2). Mean dexamethasone equivalent
dose was 5.5 mg/day [27].
Mean PROMs at baseline (EORTC QLQ-C30 0–100) are shown in Table 2. Mean EORTC
QLQ-C30 scores were above 65 points for pain, appetite and fatigue indicating severe symp-
tom intensity. Role, physical, and social function and global health were below 45 points, indi-
cating impairment in these function domains and health-related quality of life.
Table 3 shows the median serum concentration of inflammatory biomarkers (cytokines,
CRP and ESR) at study baseline. IL-1β, IL-2, IL-4, IL-8, IL-10, IL-12(p70), TNF-α, interferon-
γ, and MIP-1α values were below the lower limit of detection. Median CRP and ESR were 44
Table 1. (Continued)
Number of patients (n = 49) Mean Median CI
Ongoing cancer treatment
Radiotherapy 0
Chemotherapy 7e
Hormonal therapy 6
None 36
aBMI: Body mass index,
bKPS: Karnofsky Performance Status Score,
c IQR: Interquartile range,
dOME: Oral Morphine Equivalents,
ePaclitaxel (n = 1), Gemcitabine (n = 1), Pemetrexed (n = 1), Fluorouracil (n = 1), Fluorouracil and Irinotecan (n = 1), Fluorouracil and Leucovorin (n = 1),
Capecitabine and Temozolomide (n = 1).
https://doi.org/10.1371/journal.pone.0177620.t001
Table 2. EORTC QLQ-C30 measurements at baseline.
Mean Median CI
Physical function 39.3 40 33.8–44.8
Role function 24.8 16.7 18.4–31.2
Emotional function 73.9 75.0 67.0–80.8
Cognitive function 68.8 66.7 60.7–76.8
Social function 44.1 50.0 35.5–52.7
General health 40.5 41.7 34.8–46.1
Fatigue 72.7 77.8 66.1–79.2
Appetite loss 68.0 66.7 59.3–76.8
Pain 78.9 83.3 74.1–83.7
Nausea and vomiting 31.0 16.7 23.0–39.0
Dyspnoea 47.6 33.3 39.1–56.1
Sleep 27.8 33.3 18.6–37.0
Constipation 46.5 50.0 34.8–58.3
Diarrhoea 22.2 0,0 13.0–31.4
CI: 95% confidence interval
https://doi.org/10.1371/journal.pone.0177620.t002
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and 42, respectively, and cytokines IL-1ra, IL-6, IL-18, MCP-1, MIF, sTNF-r1 and TGF-β1
were increased as evidence of systemic inflammation.
Table 4 shows relationship between biomarkers and pain, appetite and fatigue at study base-
line. Moderate correlations were demonstrated between appetite and CRP and IL-6; and
fatigue and IL-1ra (rs = .38 - .41, p< .01). Pain was not significantly correlated with any bio-
markers. For the other EORTC PROMs, low correlations were observed.
For the EORTC function domains, strong correlations were found between physical func-
tion and CRP, IL-6 and sTNF-r1; and role function and CRP, IL-6, ESR, sTNF-r1 (rs> .50,
p< .001). Moderate correlations were found between physical function and ESR, and IL-18;
between role function and IL-18 and MIF; and between cognitive function and TGF-β1 (rs =
.40 - .50, p< .01).
Table 5 shows the relationship between serum concentrations of biomarkers at baseline and
improvement in PROMs following treatment with corticosteroids. Serum-concentration of
MCP-1 was correlated with pain intensity (β = -.38) (explained variability R2 = 0.13, p = .016),
and sTNF-r1 was correlated with appetite (β = —.43) (explained variability R2 = 0.16, p = .012)
after corticosteroid treatment, not significant when allowing for multiple comparisons.
The relationships between individual inflammatory markers are shown in Table 6. Strong
correlations were found between CRP and ESR, and IL-6; sTNF-r1 and IL-18, and MIF; IL-6
and IL-1ra, and MIF; and MCP-1 and IL-18, all correlations rs > .50 (p< .001). A number of
moderate correlations were observed (rs = .39 - .50, p< .01).
Discussion
The present study demonstrates that biomarkers of the systemic inflammatory response are
related to appetite and fatigue in patients with advanced cancer with pain who are taking opi-
oids. More specifically, decreased appetite was correlated with increased levels of IL-6 and
CRP, and increased fatigue was correlated with increased IL-1ra. In contrast, pain was not cor-
related with any of the investigated biomarkers. No significant predictor for effect of cortico-
steroid treatment was identified.
The inflammatory biomarker panel included in the present study showed increased serum
concentrations of IL-6, IL-8, MIF, sTNF-r1, and TGF-β1 in patients with advanced disease.
Interestingly, this pattern corresponds to the cytokine pattern described in patients with
advanced cancer by Lippitz [4]. It is also consistent with previous reports showing that sys-
temic inflammation is related to multiple quality of life and symptom variables [6, 13]. In this
study, IL-6 and CRP were related to deteriorating appetite, and animal studies have also
Table 3. Biomarkers and observed serum concentrations.
I Concentration (pg/mL) median Interquartile range (IQR) LLOQa
CRP 44 19.8–122.5
ESR 42 18–83.8
IL-1ra 21.7 21.7–126.8 21.7
IL-6 2.33 2.33–26.0 2.33
IL-18 103.2 73.4–164.3 1.1
MCP-1 64.1 46.9–107.3 1.5
MIF 134.9 85.4–334.2 4.8
sTNF-r1 10917 7223–15257 27.1
TGF-β1 45145 36714–52636 1.2
aLLOQ: Lower limit of quantification.
https://doi.org/10.1371/journal.pone.0177620.t003
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proposed a link between loss of appetite and systemic and regional expression of the pro-
inflammatory cytokines IL-1, TNF-α and IL-6 [28]. In other studies in patients with cancer,
associations have been shown between appetite loss and IL-1β, IL-6 and IL-8 [29] and with
gene polymorphisms coding for TNF-α [30], IL-1β [31], and IL-10 [32]. In our data, increasing
IL-6 was the most prominent biomarker for appetite loss with explained variability R2 = 0.16.
The present study also observed a moderate correlation (rs = .41) between fatigue and the
anti-inflammatory cytokine IL-1ra. IL-1ra is a physiological inhibitor of IL-1β, its production
is stimulated by IL-1β and IL-6 [33]. IL-1ra is expressed in higher concentrations in serum as
compared to IL-1β, which has a short half-life and is degraded during storage [34]. Thus, IL-
1ra serves as a marker for IL-1 activity [26, 35].
Work to date has suggested that cancer-related fatigue is linked to inflammatory, metabolic,
neuroendocrine, and genetic biomarkers [12]. However, results for individual biomarkers are
inconsistent which may be due in part to methodological issues [12]. In patients with advanced
disease, several studies have shown an association between fatigue and CRP [6, 13, 36, 37].
However, in another trial this association did not persist after correction for covariates [38]. In
one of the cited studies, IL-1ra and IL-6 were associated with fatigue in patients with advanced
cancer [36]; although this was not found for IL-6, IL-1β, IL-8 or TNF-α in another study [29].
Table 5. Fatigue, appetite and pain intensity and response to corticosteroid therapy.
Fatigue Appetite Pain intensity
β Sig R2 β Sig R2 β Sig R2
CRP 0.07 .00 0.16 .02 -0.07 .00
ESR -0.06 .00 -0.04 .00 -0.17 .03
sTNF-r1 -0.18 .03 -0.43 p = .012 .16 -0.34 p = .033 .10
IL-6 0.07 .00 -0.10 .01 -0.21 .04
MCP-1 -0.10 .01 -0.20 .03 -0.38 p = .016 .13
IL-18 -0.15 .02 -0.04 .00 -0.29 .08
MIF -0.08 .01 -0.17 .03 -0.33 p = .034 .10
TGF-β1 -0.10 .01 -0.16 .02 0.02 .00
β = standardized beta. Multiple regression analysis: fatigue day 7 dependent; fatigue day 0, sex, and BMI as
covariates. Biomarkers CRP, IL-6, IL-18, MCP-1, MIF, and TGF-β1 were log-transformed. Blood samples
were missing for CRP (n = 3) and for cytokines (n = 6).
https://doi.org/10.1371/journal.pone.0177620.t005
Table 6. Correlations between the analysed cytokines.
CRP ESR sTNF-r1 IL-1ra IL-6 MCP-1 IL-18 MIF
CRP 1
ESR 0.70** 1
sTNF-r1 0.38 0.45* 1
IL-1ra 0.32 0.28 0.21 1
IL-6 0.69** 0.49* 0.37 0.55** 1
MCP-1 -0.00 0.00 0.38 0.20 0.28 1
IL-18 0.39* 0.41* 0.59** 0.49* 0.45* 0.52** 1
MIF 0.31 0.40* 0.63** 0.32 0.54** 0.50* 0.31 1
TGF-β1 0.25 0.09 0.12 -0.12 0.16 0.15 -0.19 0.25
* = p< .01,
** = p< .001
https://doi.org/10.1371/journal.pone.0177620.t006
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In patients with advanced cancer, intensity of fatigue has been associated with other symp-
toms, in particular pain, dyspnoea, anorexia, psychological distress, and insomnia [39]. Fatigue
is commonly described in symptom clusters with pain [40, 41], and indeed the primary trial
was a pain intervention trial. Our results showed that pain intensity was associated with
fatigue, rs = .38 (p< .01) (results not tabulated). In a regression model, pain and IL-1ra were
both independently associated with fatigue, with an explained variability of R2 = 0.12 and R2 =
0.13, respectively. In three small clinical trials, IL-6 blockers [42, 43], and IL-1ra-treatment
[44], were effective in decreasing disease activity and in alleviating fatigue when used for treat-
ing IL-6-mediated Castleman’s disease. Data also indicate that treatment with recombinant
IL-1ra may alleviate fatigue in patients with rheumatoid arthritis and Sjo¨gren’s syndrome [45,
46].
In the case of pain, the positive associations between pain and CRP [5, 6, 13] reported previ-
ously were not observed in the present trial. Moreover, intervention trials assessing effects of
corticosteroids on cancer pain have also shown conflicting results. The primary trial found no
evidence of an analgesic effect of methylprednisolone 32 mg daily for cancer pain [17].
Another trial found only a temporary effect of systemic corticosteroids on pain intensity [16,
47]. This is in contrast to a previous cross-over trial [19], in which 28 patients with predomi-
nantly bone localized pain (n = 16), visceral (n = 7) or nerve compression pain (n = 5) and low
level of opioids showed response in pain intensity and analgesic consumption to methylpred-
nisolone 32 mg daily. These observations suggest that cancer pain might be less associated
with systemic inflammation than appetite and fatigue. However, the conflicting results may
also suggest that there are subgroups of cancer pain that may respond better to corticosteroid
treatment. Cancer induced bone pain might be such a subgroup. In this respect it is worth
mentioning that patients with elevated pre-treatment serum-concentrations of MCP-1 were
more likely to have an improvement in pain following treatment with corticosteroids (Table 4)
(explained variability R2 = 0.13, p = .016, not significant when allowing for multiple compari-
sons). Correcting for the presence of cancer induced bone pain did not influence this result.
This observation corresponds to previous work that MCP-1 plays a role in chronic pain
facilitation via its receptor, C-C chemokine receptor type 2 (CCR2) [48, 49]. Animal data show
that MCP-1 expression in spinal neurons also is increased in animals with cancer induced
bone pain. Moreover, MCP-1 induced hyperalgesia and anti-MCP-1 or CCR2 agonist attenu-
ated hyperalgesia in animals with bone cancer when applied intrathecally [50, 51]. Further-
more, corticosteroids are shown to decrease MCP-1 [52]. Additionally, experimental animal
studies suggest that locally applied sustained release methylprednisolone improved hyperalge-
sia in rats with compression radicular pain. This pain improvement was associated with a
decreased number of infiltrating macrophages at the sciatic nerve, and reduced MCP-1 expres-
sion in the nerve [53]. In patients with cancer pain, MCP-1 was one of five cytokines that was
significantly correlated with pain relief in a study on acute changes in cytokine serum concen-
trations during three hours of opioid treatment for pain [54]. Based on this basic science work,
the observation that MCP-1 might be a biomarker for pain response from corticosteroids is
interesting and should be tested in future studies.
A number of correlations were observed between biomarkers and EORTC function
domains, in particular for deteriorating physical and role function which were associated with
increasing CRP, IL-6, sTNF-r1, ESR, IL-18, and MIF. Multiple regression analyses showed that
CRP was the most strongly correlated biomarker for role function, and IL-6 for physical func-
tion, with explained variability R2adjusted = 0.34 and 0.28, respectively. Role function comprises
two items, i.e. ability to perform work or to pursue hobby activity, while physical function
items focus on physical capability and strength. Role and physical function items are closely
related [55] and do probably express the same construct. Moreover, poor role function may
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also be related to high intensity of cancer-related fatigue in this cohort. We have identified two
studies that report a multidimensional assessment of fatigue in patients with advanced cancer.
These two trials observed associations with cytokines IL-1ra or IL-6, respectively, of the physi-
cal fatigue subscale only and not of the mental dimensions of fatigue [56, 57]. The EORTC
fatigue item has been shown to correlate more strongly with the physical than the mental
fatigue subscale of the Fatigue Questionnaire in palliative care patients [58]. Fatigue, but not
pain intensity, was significantly associated with role function in our data, rs = .54 (p< .001)
(results not tabulated).
In our study, a correlation was also demonstrated between cognitive function, i.e. difficulty
in concentrating and remembering things, and increasing serum concentrations of the anti-
inflammatory cytokine TGF-β1. Data from patients with breast cancer suggest that IL-1β, IL-6,
IL-8 and TNF-α contribute to chemotherapy-associated cognitive impairment [59]. Cognitive
symptoms are frequent in patients receiving cytokine-based immunotherapies such as inter-
feron-α and IL-2 [60]. However, an association between TGF-β1 and cognitive function is not
previously described in results from clinical trials to the best of our knowledge.
In the multiple regression analyses, appetite was independently associated with IL-6 and
CRP; and fatigue independently associated with IL-1ra. As for the EORTC function scales,
only role function was independently associated with CRP and IL-6. These results support the
clinical observations seen in the primary trial in which appetite and fatigue were statistically
and clinically significantly improved after anti-inflammatory treatment with methylpredniso-
lone [17]. Moreover, these observations also correspond to findings from another trial show-
ing that dexamethasone improved fatigue and physical well-being [16]. Similarly, appetite,
fatigue, and role function were the only EORTC QLQ-C30 items independently associated
with systemic inflammation in patients with advanced cancer in a large, recent study [13].
Taken together, these data representing both cross-sectional data and intervention trials sup-
port systemic inflammation as a plausible causal factor in fatigue, reduced appetite, and
impaired role functioning.
Persuasive arguments now support a move towards assessing the clinical usefulness of spe-
cific inhibitors of inflammation in treating or preventing symptoms caused by innate immune
reactions in cancer. This type of studies will also provide further information regarding the
possible role of cytokines in the pathophysiology of these symptoms. As for today, recombi-
nant IL-1ra (anakinra) is one example of a viable therapeutic option, and intervention trials on
IL-1ra administration for chronic fatigue syndrome are underway [61].
We recognize that the present study has some limitations. We included a limited number of
patients, making the analyses susceptible to imprecise estimates and type II errors. In addition,
we did not obtain blood samples after the intervention period and therefore we cannot com-
pare PROMs with changes in cytokine concentrations after corticosteroid treatment. Another
limitation is that this was a small sample with marked heterogeneity of the population studied,
factors which may have influenced the findings. Also, the time of sampling was not strictly
standardized. The diurnal variation of certain cytokines could influence the results as for
instance IL-1, IL-6, TNF-α, and interferon-γ are linked to melatonin and have their peak early
in the morning [8, 34].
It is also worth mentioning that as all patients in the study were taking opioids. The role of
opioids in immune modulation is well documented [62, 63]. The immune modulatory effects
may differ between opioids [63, 64]; and how they may affect the different cytokines is not well
defined. Serum concentrations of cytokines were not associated with oral morphine equiva-
lents in our study, and no differences were observed between morphine, oxycodone or fenta-
nyl. However, sample size did not allow subgroup analyses. Additionally, as opioids may
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attenuate pain, and adverse effects may result in fatigue, all these factors may have influenced
the findings.
However, to our knowledge, this is the first study assessing associations between inflamma-
tory biomarkers and PROMs in the setting of an intervention trial with corticosteroids.
Conclusion
Symptoms in patients with advanced cancer have been regarded as related to the underlying
tumor bulk and its physiological consequences. However, the tumour-host interaction is likely
to play an important role in symptom development and certain symptoms may be related to
individual cytokines implicated in the pro-inflammatory response [65].
We report an association between inflammatory markers IL-6 and CRP and appetite, and
IL-1ra and fatigue in cancer patients with advanced disease. Additionally, independent associ-
ations between role function and CRP and IL-6 were prominent. Whether or not these cyto-
kines are responsible, in isolation or in conjunction with others, for the development or the
progression of symptoms, remains unclear and is beyond the scope of the present study. How-
ever, the demonstration of the importance of systemic inflammation in the likelihood of
responding to anti-cancer therapy [66], may be a paradigm that can be applied to symptoms.
Our findings provide further weight to the argument that the systemic inflammatory response
influences symptoms, specifically anorexia and fatigue, in cancer patients. Studies testing this
hypothesis are needed and may have the potential to improve symptom control in patients
with advanced cancer.
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